At Orano Med, the fight against cancer is paramount.
In Brownsburg, something revolutionary stirs within the freshly inaugurated ATLab, an expansive and state-of-the-art facility dedicated to changing the landscape of oncology. Orano Med, a French trailblazer in the field of biotechnology, is at the forefront of this transformation, focusing its sharp intellect and resources on the battle against cancer. With a deep investment of $20 million and sprawling across 30,000 square feet, Orano Med’s newest installation is poised to redefine cancer therapy with its pioneering lead-212 radioligand treatments.
A Leap Towards Targeted Alpha Therapy
The principal weapon in Orano Med’s arsenal is lead-212 (212Pb), a rare alpha-emitting radioisotope with formidable potential against cancer cells, marking the advent of Targeted Alpha Therapy (TAT). This innovative approach combines the precision of biological
molecules in finding cancer cells with alpha emissions’ potent, localized destructive power.
The endgame? A portfolio of treatments that promises hope and a tangible method to combat various cancers more efficiently and with potentially fewer side effects than traditional therapies.
Catalyzing a Revolution in Oncology
June 2024 saw the inauguration of ATLab Indianapolis, distinguishing it as the world’s first industrial-scale pharmaceutical facility dedicated to the craft of lead-212 radioligand therapies. Situated at 1145 E Northfield Dr., the opening of this laboratory is a significant leap forward, especially for patients in North America with urgent needs for innovative treatment options.
Orano Med’s stride towards an entirely chemical production process of lead-212 underlines a commitment to reliability, reduced costs, and independence from the conventional, more cumbersome methods of radioisotope production. This development heralds a new era of
manufacturing and distribution for radiopharmaceuticals, addressing longstanding challenges and meeting the critical demand for these therapies on a large scale.
“We are convinced that lead-212 radioligand therapies will soon become an essential tool in the fight against cancer,” said Orano Med CEO Julien Dodet Having obtained, together with our partner RadioMedix, Breakthrough Therapy Designation (BTD) from the FDA for our most advanced drug AlphaMedix, the inauguration of ATLab Indianapolis represents another major step forward in the development, production, and distribution of these new treatments on a large scale.”
Global Impact from Brownsburg
The strategic location of ATLab Indianapolis is no coincidence. Given the half-life of lead-212, just over 10 hours, the drugs must be produced close to hospitals or located in areas with easy transportation access on a global scale. Chosen for its proximity to major national and international distribution networks, with the second-largest FedEx hub and its rapidly expanding life sciences ecosystem, Brownsburg is set to play a crucial role in meeting the global demand for these groundbreaking treatments. With a forecast to manufacture 10,000 doses annually by 2025 and ambitions to escalate production tenfold by the decade’s end, ATLab Indianapolis is gearing up to substantially impact the world stage.
ATLab Indianapolis stands as a landmark in Orano’s expansion in the US, according to Guillaume Dureau, Orano Group Senior Executive Vice-President of Projects & Innovation R&D and Nuclear Medicine. This facility, together with the Plano, Texas research unit, positions Orano to meet the demands of North American patients needing target-specific lead-212 radiotherapy treatments.
Moreover, the new facility has fueled local job creation, adding 25 new positions in Brownsburg and reinforcing Indiana’s reputation as a hub for highly skilled talent in the life sciences sector. Tony Denhart, Executive Vice President of Talent and Workforce at the Indiana Economic Development Corporation, notes that Indiana’s talent pipeline includes nationally ranked universities and has proven it’s ready to fill new roles, allowing companies to not only succeed but grow in Indiana.
A New Chapter in Cancer Treatment
As Orano Med, alongside its esteemed partners, paves the way for these transformative cancer therapies, the ATLab Indianapolis stands as a testament to human ingenuity and the relentless pursuit of medical advancement. It’s a compelling chapter in the ongoing story of how science, commitment, and collaboration can converge to offer new hope in the fight against cancer.
